Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy

In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the musc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical investigation 2007-12, Vol.117 (12), p.3952-3957
Hauptverfasser: Wheeler, Thurman M, Lueck, John D, Swanson, Maurice S, Dirksen, Robert T, Thornton, Charles A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3957
container_issue 12
container_start_page 3952
container_title The Journal of clinical investigation
container_volume 117
creator Wheeler, Thurman M
Lueck, John D
Swanson, Maurice S
Dirksen, Robert T
Thornton, Charles A
description In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.
doi_str_mv 10.1172/jci33355
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2075481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A172599262</galeid><sourcerecordid>A172599262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</originalsourceid><addsrcrecordid>eNqNkktr3DAUhb1oSdKk0F9QtCrtwqmefmwKwfQxJRBIH1sjS1e2giy5lifU_76aztBmIIsgoSt0v3sWRyfLXhF8SUhJ398pyxgT4ll2hjEleV2y6jR7EeMdxoRzwU-yU1JhnHZ9lv1qwjyDWmzwKBjUuCYnKE7OKut7BM6O1ssFIlKDC7PVkC7Se3BhksuwIuk1GtewBG8lsh6NYRshnRpc3AkeegrpNS5zmIb1IntupIvw8lDPsx-fPn5vvuTXN583zdV1rkRRiLwQmhOuuxKIqBgGKmnBuKGmK0qiDead7LoaV5yyQmNSsgJTXbFaEMWFYZKdZx_2utO2G0Er8MssXTvNdpTz2gZp2-OOt0Pbh_uW4lLwiiSBfC_QSwet9SYkTPXgIdHBg7Hp-SpZLuqaFjTxl4_waWkYrXp04N3RQGIW-L30chtju_l2-3T25ucx--YBO4B0yxCD2-4-OR6Db_egmkOMM5h_7hDc7sLUfm02f8OU0NcP3fwPHpLE_gD8HcV_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</creator><creatorcontrib>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</creatorcontrib><description>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci33355</identifier><identifier>PMID: 18008009</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Action Potentials - drug effects ; Action Potentials - genetics ; Alternative Splicing - drug effects ; Alternative Splicing - genetics ; Animals ; Channelopathies - drug therapy ; Channelopathies - genetics ; Channelopathies - metabolism ; Chloride channels ; Chloride Channels - biosynthesis ; Chloride Channels - genetics ; Exons - genetics ; Genetic aspects ; Genetic engineering ; Health aspects ; Methods ; Mice ; Myotonia Congenita - drug therapy ; Myotonia Congenita - genetics ; Myotonia Congenita - metabolism ; Myotonic dystrophy ; Myotonic Dystrophy - drug therapy ; Myotonic Dystrophy - genetics ; Myotonic Dystrophy - metabolism ; Oligodeoxyribonucleotides, Antisense - pharmacology ; Oligodeoxyribonucleotides, Antisense - therapeutic use ; Risk factors ; RNA Splice Sites - genetics ; Sarcolemma - genetics ; Sarcolemma - metabolism</subject><ispartof>The Journal of clinical investigation, 2007-12, Vol.117 (12), p.3952-3957</ispartof><rights>COPYRIGHT 2007 American Society for Clinical Investigation</rights><rights>Copyright © 2007, American Society for Clinical Investigation 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</citedby><cites>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075481/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075481/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18008009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wheeler, Thurman M</creatorcontrib><creatorcontrib>Lueck, John D</creatorcontrib><creatorcontrib>Swanson, Maurice S</creatorcontrib><creatorcontrib>Dirksen, Robert T</creatorcontrib><creatorcontrib>Thornton, Charles A</creatorcontrib><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</description><subject>Action Potentials - drug effects</subject><subject>Action Potentials - genetics</subject><subject>Alternative Splicing - drug effects</subject><subject>Alternative Splicing - genetics</subject><subject>Animals</subject><subject>Channelopathies - drug therapy</subject><subject>Channelopathies - genetics</subject><subject>Channelopathies - metabolism</subject><subject>Chloride channels</subject><subject>Chloride Channels - biosynthesis</subject><subject>Chloride Channels - genetics</subject><subject>Exons - genetics</subject><subject>Genetic aspects</subject><subject>Genetic engineering</subject><subject>Health aspects</subject><subject>Methods</subject><subject>Mice</subject><subject>Myotonia Congenita - drug therapy</subject><subject>Myotonia Congenita - genetics</subject><subject>Myotonia Congenita - metabolism</subject><subject>Myotonic dystrophy</subject><subject>Myotonic Dystrophy - drug therapy</subject><subject>Myotonic Dystrophy - genetics</subject><subject>Myotonic Dystrophy - metabolism</subject><subject>Oligodeoxyribonucleotides, Antisense - pharmacology</subject><subject>Oligodeoxyribonucleotides, Antisense - therapeutic use</subject><subject>Risk factors</subject><subject>RNA Splice Sites - genetics</subject><subject>Sarcolemma - genetics</subject><subject>Sarcolemma - metabolism</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkktr3DAUhb1oSdKk0F9QtCrtwqmefmwKwfQxJRBIH1sjS1e2giy5lifU_76aztBmIIsgoSt0v3sWRyfLXhF8SUhJ398pyxgT4ll2hjEleV2y6jR7EeMdxoRzwU-yU1JhnHZ9lv1qwjyDWmzwKBjUuCYnKE7OKut7BM6O1ssFIlKDC7PVkC7Se3BhksuwIuk1GtewBG8lsh6NYRshnRpc3AkeegrpNS5zmIb1IntupIvw8lDPsx-fPn5vvuTXN583zdV1rkRRiLwQmhOuuxKIqBgGKmnBuKGmK0qiDead7LoaV5yyQmNSsgJTXbFaEMWFYZKdZx_2utO2G0Er8MssXTvNdpTz2gZp2-OOt0Pbh_uW4lLwiiSBfC_QSwet9SYkTPXgIdHBg7Hp-SpZLuqaFjTxl4_waWkYrXp04N3RQGIW-L30chtju_l2-3T25ucx--YBO4B0yxCD2-4-OR6Db_egmkOMM5h_7hDc7sLUfm02f8OU0NcP3fwPHpLE_gD8HcV_</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Wheeler, Thurman M</creator><creator>Lueck, John D</creator><creator>Swanson, Maurice S</creator><creator>Dirksen, Robert T</creator><creator>Thornton, Charles A</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>5PM</scope></search><sort><creationdate>200712</creationdate><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><author>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Action Potentials - drug effects</topic><topic>Action Potentials - genetics</topic><topic>Alternative Splicing - drug effects</topic><topic>Alternative Splicing - genetics</topic><topic>Animals</topic><topic>Channelopathies - drug therapy</topic><topic>Channelopathies - genetics</topic><topic>Channelopathies - metabolism</topic><topic>Chloride channels</topic><topic>Chloride Channels - biosynthesis</topic><topic>Chloride Channels - genetics</topic><topic>Exons - genetics</topic><topic>Genetic aspects</topic><topic>Genetic engineering</topic><topic>Health aspects</topic><topic>Methods</topic><topic>Mice</topic><topic>Myotonia Congenita - drug therapy</topic><topic>Myotonia Congenita - genetics</topic><topic>Myotonia Congenita - metabolism</topic><topic>Myotonic dystrophy</topic><topic>Myotonic Dystrophy - drug therapy</topic><topic>Myotonic Dystrophy - genetics</topic><topic>Myotonic Dystrophy - metabolism</topic><topic>Oligodeoxyribonucleotides, Antisense - pharmacology</topic><topic>Oligodeoxyribonucleotides, Antisense - therapeutic use</topic><topic>Risk factors</topic><topic>RNA Splice Sites - genetics</topic><topic>Sarcolemma - genetics</topic><topic>Sarcolemma - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wheeler, Thurman M</creatorcontrib><creatorcontrib>Lueck, John D</creatorcontrib><creatorcontrib>Swanson, Maurice S</creatorcontrib><creatorcontrib>Dirksen, Robert T</creatorcontrib><creatorcontrib>Thornton, Charles A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wheeler, Thurman M</au><au>Lueck, John D</au><au>Swanson, Maurice S</au><au>Dirksen, Robert T</au><au>Thornton, Charles A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2007-12</date><risdate>2007</risdate><volume>117</volume><issue>12</issue><spage>3952</spage><epage>3957</epage><pages>3952-3957</pages><issn>0021-9738</issn><abstract>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>18008009</pmid><doi>10.1172/jci33355</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 2007-12, Vol.117 (12), p.3952-3957
issn 0021-9738
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2075481
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Action Potentials - drug effects
Action Potentials - genetics
Alternative Splicing - drug effects
Alternative Splicing - genetics
Animals
Channelopathies - drug therapy
Channelopathies - genetics
Channelopathies - metabolism
Chloride channels
Chloride Channels - biosynthesis
Chloride Channels - genetics
Exons - genetics
Genetic aspects
Genetic engineering
Health aspects
Methods
Mice
Myotonia Congenita - drug therapy
Myotonia Congenita - genetics
Myotonia Congenita - metabolism
Myotonic dystrophy
Myotonic Dystrophy - drug therapy
Myotonic Dystrophy - genetics
Myotonic Dystrophy - metabolism
Oligodeoxyribonucleotides, Antisense - pharmacology
Oligodeoxyribonucleotides, Antisense - therapeutic use
Risk factors
RNA Splice Sites - genetics
Sarcolemma - genetics
Sarcolemma - metabolism
title Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A56%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correction%20of%20ClC-1%20splicing%20eliminates%20chloride%20channelopathy%20and%20myotonia%20in%20mouse%20models%20of%20myotonic%20dystrophy&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Wheeler,%20Thurman%20M&rft.date=2007-12&rft.volume=117&rft.issue=12&rft.spage=3952&rft.epage=3957&rft.pages=3952-3957&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci33355&rft_dat=%3Cgale_pubme%3EA172599262%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18008009&rft_galeid=A172599262&rfr_iscdi=true